Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Involvement of FoxM1 in Non-Small Cell Lung Cancer Recurrence

  • Xu, Nuo (Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University) ;
  • Wu, Sheng-Di (Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University) ;
  • Wang, Hao (Department of Thoracology, Zhongshan Hospital, Fudan University) ;
  • Wang, Qun (Department of Thoracology, Zhongshan Hospital, Fudan University) ;
  • Bai, Chun-Xue (Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University)
  • Published : 2012.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Predictive biomarkers for lung cancer recurrence after curative tumor resection remain unclear. This study set out to assess the role of FoxM1 in the recurrence of non-small cell lung cancer. Methods: Immunohistochemistry for FoxM1 expression was performed on paraffin-embedded tumor tissues from 165 NSCLC patients. Association of FoxM1 expression with clinicopathological parameters and disease free survival were evaluated. Results: Our results indicated FoxM1 expression to be significantly associated with poorer tissue differentiation (P =0.03), higher TNM stage (P <0.01), lymph node metastasis (P <0.01), advanced tumor stage (P <0.01), and poorer disease free survival (P <0.01). Multivariable analysis showed that FoxM1 expression increased the hazard of recurrence (hazard ratio= 1.96, 95% CI, 1.04-3.17, P <0.05), indicating that FoxM1 is an independent and significant predictor of lung cancer recurrence. Conclusion: Therefore, FoxM1 is an independent risk factor for recurrence of NSCLC. Elevated FoxM1 expression could be used as an indicator of poor disease free survival.

Keywords

References

  1. Chen CH, Chien CY, Huang CC, et al (2009). Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. Oncogene, 28, 2723-37. https://doi.org/10.1038/onc.2009.128
  2. Chu XY, Zhu ZM, Chen LB, et al (2012). FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. Acta Histochem, 2012 Feb 10. Acta Histochem, 114, 755-62. https://doi.org/10.1016/j.acthis.2012.01.002
  3. Douillard JY, Rosell R, De Lena M, et al (2006). Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol, 7, 719-27. https://doi.org/10.1016/S1470-2045(06)70804-X
  4. Gibbons DL, Lin W, Creighton CJ, et al (2009). Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One, 4, e5401. https://doi.org/10.1371/journal.pone.0005401
  5. Javelaud D, Pierrat MJ, Mauviel A (2012). Crosstalk between TGF-beta and hedgehog signaling in cancer. FEBS Lett, 586, 2016-25. https://doi.org/10.1016/j.febslet.2012.05.011
  6. Kalin TV, Wang IC, Ackerson TJ, et al (2006). Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res, 66, 1712-20. https://doi.org/10.1158/0008-5472.CAN-05-3138
  7. Kim IM, Ackerson T, Ramakrishna S, et al (2006). The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res, 66, 2153-61. https://doi.org/10.1158/0008-5472.CAN-05-3003
  8. Kwok JM, Peck B, Monteiro LJ, et al (2010). FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res, 8, 24-34. https://doi.org/10.1158/1541-7786.MCR-09-0432
  9. Lagerwaard FJ, Senan S, van Meerbeeck JP, et al (2002). Has 3-D conformal radiotherapy (3D CRT) improved the local tumour control for stage I non-small cell lung cancer? Radiother Oncol, 63, 151-7. https://doi.org/10.1016/S0167-8140(02)00009-9
  10. Liu YQ, Guo RH, Liu LK, et al (2011). Correlation between expression of forkhead box M1 (FOXM1) and clinicopathological features and prognosis in patients with non-small cell lung cancer (NSCLC). Zhonghua Zhong Liu Za Zhi, 33, 426-30.
  11. Martini N, Bains MS, Burt ME, et al (1995). Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg, 109, 120-9. https://doi.org/10.1016/S0022-5223(95)70427-2
  12. Park HJ, Carr JR, Wang Z, et al (2009). FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J, 28, 2908-18. https://doi.org/10.1038/emboj.2009.239
  13. Park HJ, Gusarova G, Wang Z, et al (2011). Deregulation of FoxM1b leads to tumour metastasis. EMBO Mol Med, 3, 21-34. https://doi.org/10.1002/emmm.201000107
  14. Rami-Porta R, Ball D, Crowley J, et al (2007). The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol, 2, 593-602. https://doi.org/10.1097/JTO.0b013e31807a2f81
  15. Rowell NP, Williams CJ (2001). Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. Thorax, 56, 628-38. https://doi.org/10.1136/thorax.56.8.628
  16. Sobin L, Gospodarowicz M, Wittekind C (2009). TNM Classification of Malignant Tumors,TNM Classification of Malignant Tumors,. 7th Ed Geneva, UICC International Union Against Cancer, pp136-46.
  17. Travis K (2004). Lung cancer screening for all? Not yet, panel says. J Natl Cancer Inst, 96, 900-1. https://doi.org/10.1093/jnci/96.12.900
  18. Uchida A, Hirano S, Kitao H, et al (2007). Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Sci, 98, 357-63. https://doi.org/10.1111/j.1349-7006.2007.00387.x
  19. Wang IC, Meliton L, Tretiakova M, et al (2008). Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors. Oncogene, 27, 4137-49. https://doi.org/10.1038/onc.2008.60
  20. Wang Z, Banerjee S, Kong D, et al (2007). Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res, 67, 8293-300. https://doi.org/10.1158/0008-5472.CAN-07-1265
  21. Xia JT, Wang H, Liang LJ, et al (2012). Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma. Pancreas, 41, 629-35. https://doi.org/10.1097/MPA.0b013e31823bcef2
  22. Xu N, Zhang X, Wang X, et al (2012). FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells. Acta Pharmacol Sin, 33, 675-81. https://doi.org/10.1038/aps.2011.188
  23. Yoshida Y, Wang IC, Yoder HM, et al (2007). The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. Gastroenterology, 132, 1420-31. https://doi.org/10.1053/j.gastro.2007.01.036

Cited by

  1. High FOXM1 expression was associated with bladder carcinogenesis vol.34, pp.2, 2013, https://doi.org/10.1007/s13277-013-0654-x
  2. Induction of Indoleamine 2,3-dioxygenase (IDO) Enzymatic Activity Contributes to Interferon-Gamma Induced Apoptosis and Death Receptor 5 Expression in Human Non-small Cell Lung Cancer Cells vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7995
  3. Comprehensive Expression Analysis Suggests Functional Overlapping of Human FOX Transcription Factors in Cancer vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10475
  4. Immunohistochemistry-based prognostic biomarkers in NSCLC: novel findings on the road to clinical use? vol.15, pp.4, 2015, https://doi.org/10.1586/14737159.2015.1002772
  5. FoxM1 as a Novel Therapeutic Target for Cancer Drug Therapy vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.23
  6. SUMO-specific protease 6 promotes gastric cancer cell growth via deSUMOylation of FoxM1 vol.36, pp.12, 2015, https://doi.org/10.1007/s13277-015-3737-z